Sign in
CompletedPhase 3

Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects

Key facts

Who runs it
AiCuris Anti-infective Cures AG
Where
Atlanta, Baltimore, Baton Rouge, Birmingham, Boston, Brooklyn, Burr Ridge, Chicago, Cincinnati, Decatur, DeLand, Duarte, Durham, Ft. Pierce, Gainesville, Hershey, Houston, Huntsville, Lee's Summit, Los Angeles, Miami, Minneapolis, Mobile, New Brunswick, New Orleans, New York, Omaha, Pittsburgh, Sacramento, Seattle, Tampa, Tucson, and Winston-Salem, United StatesSee the 33 sitesAlso in 14 other countries, 37 sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
158 people enrolled
Started
8 May 2017
Ended
11 Nov 2025
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Pritelivir
  • Investigator's choice
Record updated
12 June 2026

Who can take part

Age
16 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 24 criteriaShow less

Other criteria

  • Part C inclusion criteria
  • Immunocompromised men and women of any ethnic group aged ≥16 years; In Canada, Germany, Belgium:; Immunocompromised (due to conditions including but not limited to HIV infection, hematopoietic cell or solid organ transplantation, and chronic use of immunosuppressive treatment) men and women of any ethnic group aged >18 years
  • ACV-R mucocutaneous HSV infection based on clinical failure or positive genotypic/phenotypic ACV resistance testing for current lesion. Clinical failure is defined as no improvement after oral or iv doses for at least 7 days at doses equivalent to or greater than the local agency approved high oral doses of acyclovir, valacyclovir or famciclovir
  • Lesions accessible for visual inspection to allow assessment of lesion healing including visualization by endoscopy
  • Willingness to use highly effective birth control
  • Subject, and/or their legally authorized representative, (proxy consent is not permitted in Germany), must be willing and able to understand the Informed Consent Form
  • Negative serum β-HCG (beta-human chorionic gonadotropin) test for women of child-bearing potential at Screening and a negative urine pregnancy test at Day 1
  • Written informed consent. For subjects, who are unable to provide informed consent for whatever reason, written consent must be obtained from the legal representative, (proxy consent is not permitted in Germany); Part D and F inclusion criteria; All inclusion criteria as for Part C, except for inclusion criterion 2, which is replaced by:
  • ACV-R and foscarnet-R mucocutaneous HSV infection based on clinical failure or positive genotypic/phenotypic resistance testing for current lesion or documented intolerance to iv foscarnet requiring cessation of foscarnet treatment or precluding foscarnet treatment; Subjects will be able to enter Part F only after closure of enrollment in Part D; Part E inclusion (Part E is not being conducted in Germany); All inclusion criteria as for Part C, except for inclusion criterion 2, which is replaced by:
  • Recurrent mucocutaneous HSV infection considered ACV-S; Part C exclusion criteria
  • Known resistance/intolerance to pritelivir or any of the excipients
  • Previous treatment in PRIOH-1
  • Baseline safety laboratory abnormalities
  • History or current evidence of gastrointestinal malabsorption which, in the opinion of the Investigator, may affect the extent of absorption of pritelivir
  • Hemodialysis for any indication and ESRD (eGFR <15 mL/min; stage 5 CKD)
  • History or current evidence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, hematological, endocrinological, metabolic, neurological, psychiatric, or other relevant diseases
  • Abnormalities in hematological, clinical chemical or any other laboratory variables
  • Not able to communicate meaningfully with the Investigator and site staff
  • Any other condition which in the opinion of the Investigator would interfere with successful completion of this clinical trial
  • Any other important local condition
  • Pregnant and/or breastfeeding women
  • Having received an investigational drug in an investigational drug trial unter certain conditions; Part D (complete) exclusion criteria; All exclusion criteria as for Part C, except criterion 12, which is replaced by:
  • Having received an investigational drug in an investigational trial within 7 half-lives after the last administration of this drug before initiating trial medication, except for subjects entering Part D, who have previously received foscarnet treatment in Part C of this trial; Participation in a clinical trial without receiving other investigational drugs (eg, follow-up phase of a trial, observational study) is permitted; Part E exclusion criteria (Part E is not being conducted in Germany); All exclusion criteria in Part E are identical to those in Part C with the addition of:
  • Having used acyclovir, valacyclovir, or famciclovir within 3 days prior to starting pritelivir; Part F exclusion criteria All exclusion criteria for Part D plus 13. Part D open for enrollment

Where in United States

Also in 14 other countries, 37 sites

  • Emory Hospital Midtown Infectious Disease ClinicAtlanta, United States
  • Johns Hopkins University School Of MedicineBaltimore, United States
  • LSU Health Baton Rouge Pulmonary ClinicBaton Rouge, United States
  • University of Alabama at BirminghamBirmingham, United States
  • Brigham and Women's HospitalBoston, United States
  • Kings Country Hospital CenterBrooklyn, United States
  • Metro Infectious Disease Consultants, LLCBurr Ridge, United States
  • Department of Medicine J. H. Stroger Hospital of Cook CountyChicago, United States
  • Cincinnati Children's Hospital Medical CenterCincinnati, United States
  • Metro Infectious Disease Consultants - AtlantaDecatur, United States
  • Midland Florida Clinical Research Center, LLCDeLand, United States
  • City of HopeDuarte, United States
  • Duke University Medical Center - Division of Infectious DiseasesDurham, United States
  • Midway Immunology and Research Center (MIRC)Ft. Pierce, United States
  • University of Florida (UF) - Division of Infectious DiseaseGainesville, United States
  • Penn State Health Milton S. Hershey Medical CenterHershey, United States
  • MD Anderson Cancer CenterHouston, United States
  • Metro Infectious Disease Consultants, LLC - HuntsvilleHuntsville, United States
  • Lee's Summit MO United States 64086Lee's Summit, United States
  • Cedars-Sinai Medical CenterLos Angeles, United States
  • Links Clinical TrialsMiami, United States
  • University of MinnesotaMinneapolis, United States
  • University of South AlabamaMobile, United States
  • Rutgers, Robert Wood Johnson Medical SchoolNew Brunswick, United States
  • Tulane University School of MedicineNew Orleans, United States
  • David H. Koch Center at Memorial Sloan Kettering Cancer CenterNew York, United States
  • University of Nebraska Medical CenterOmaha, United States
  • University of Pittsburgh Medical CenterPittsburgh, United States
  • University of California, Division of Infectious DiseasesSacramento, United States
  • Fred Hutchinson Cancer Research CenterSeattle, United States
  • University of South FloridaTampa, United States
  • University Arizona - Department of Medicine Arizona Health Sciences CenterTucson, United States
  • Atrium Health Wake Forest BaptistWinston-Salem, United States

About the trial

What the trial wants to find out

Randomized, open-label, multi-center, comparative trial to assess the efficacy and safety in immunocompromised subjects with acyclovir resistant or acyclovir susceptible mucocutaneous HSV infection, treated with pritelivir 100 mg once daily (following a loading dose of 400 mg as first dose to rapidly reach steady-state plasma concentration) or investigators choice, which can be either foscarnet 40 mg/kg every 8 hours or 60 mg/kg every 12 hours, or Cidofovir iv 5 mg/kg body weight given once weekly, or Cidofovir 1% or 3% topical applied 2 to 4 times daily, or Imiquimod 5% topical 3 times per week) (provided the drug is nationally approved).

The 4 groups in the trial

  • Part C, PritelivirTreatment being tested

    Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days

    Treatment: Pritelivir

  • Part C,Existing treatment, for comparison

    Investigator's Choice: Foscarnet iv, 40 mg/kg tid or 60mg/kg bid or Cidofovir iv, 5 mg/kg body weight given once weekly or Cidofovir 1% or 3%, topically applied 2 to 4 times daily or Imiquimod 5%, topically applied 3 times per week, for up to 28 days and potential prolongation for up to additional 14 days.

    Treatment: Investigator's choice

  • Part D+F, PritelivirTreatment being tested

    Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days

    Treatment: Pritelivir

  • Part E, PritelivirTreatment being tested

    Oral tablets, 100mg/day (400mg loading dose on day 1) for up to 28 days and potential prolongation for up to additional 14 days

    Treatment: Pritelivir

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Open Label, Multi-center, Comparative Trial, to Assess the Efficacy and Safety of Pritelivir for the Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects (PRIOH-1)
Record updated
12 June 2026